Phaseline

Targets › TREM2

TREM2 (Triggering receptor expressed on myeloid cells 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Respiratory.

Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding. Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia. (UniProt, Q9NZC2)

Open in Phaseline: the race on TREM2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
aTyr Pharmaefzofitimod
TREM2 agonist
TREM2Phase 2Interstitial Lung Disease–

Conditions

Interstitial Lung Disease (1)

Modalities

small molecule (1)

Companies

aTyr Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.